Chimeric faces recapitalisation test as trading suspension and safety setback deepen

CHM-2101 trial stopped after safety review

Chimeric Therapeutics Limited (ASX:CHM) has ended enrolment and dosing in its Phase 1/2 CHM-2101 trial after the independent Safety Monitoring Committee determined that Dose Level 3 was unsafe and that adverse events had triggered the study’s stopping rule.

The decision marks a sharp reversal from the company’s July tumour-shrinkage results, which showed reductions of 17% to 40% in individual lesions and stable disease lasting six months and four months in two patients treated at the 450 million-cell dose. Chimeric said a second patient among the four treated at that dose later experienced non-fatal dose-limiting toxicities, while the most recently treated patient suffered Grade 3 gastrointestinal fistula, rectal pain and pelvic infection that the committee considered probably related to CHM-2101.

Board abandons current autologous product

Chimeric’s preliminary review of 14 treated patients identified anti-tumour activity, tumour-marker reductions and persistence of the CAR-T cells for up to 15 months. But the company said the dose levels required to achieve that activity were not tolerated within an acceptable safety margin using the current autologous product. The Board therefore decided not to progress CHM-2101 in its present form, with remaining patients to be followed under the trial protocol.

The company is instead considering an in vivo CDH17 programme, in which the CAR construct would be delivered directly to patients rather than manufactured as an autologous cell product. Chimeric said its University of Pennsylvania licence covers the approach, but the proposal remains preclinical, no development candidate has been selected and initial animal feasibility work depends on securing additional funding. The CORE-NK investigator-led study continues without company funding or support.

Cash position leaves little room for delay

Chimeric finished September with $1.35 million in cash and cash equivalents, after a $1.68 million operating cash outflow for the quarter. Staff costs and research and development accounted for 70% of operating outflows. Financing inflows of $2.24 million, including $1.62 million advanced against the anticipated FY2026 research and development tax incentive and $650,000 from convertible debt, lifted the cash balance from $800,000 at June 30.

On the quarterly cash-flow measure, that balance represented an estimated 0.80 quarters of funding, below the two-quarter threshold requiring additional disclosure. Chimeric expects December-quarter spending to fall after the clinical wind-down, with cash directed towards essential operations, a minimal R&D programme and any creditor settlements. That lower spending rate is an estimate rather than a source of committed funding.

Suspension and recapitalisation remain unresolved

The company’s securities remain suspended after audited FY2026 accounts missed the September 30 deadline. The filing repeats the approximately $7.7 million net asset deficiency disclosed in the company’s September trading suspension, and says the accounts are expected to contain a material uncertainty related to going concern.

Chimeric is negotiating binding settlements with creditors, including the provider of its convertible note facility, while pursuing a recapitalisation. It said it had received interest in recapitalising the company subject to sustainable balance-sheet changes, but provided no certainty on whether a transaction will proceed, or its terms or timing. The company has also reduced headcount, US operations, manufacturing and clinical expenditure, with annualised savings estimated at about $4 million after initial termination costs.

A reduced three-person Board now comprises Interim Chairman Phillip Hains, Professor Miles Prince and Managing Director Rebecca McQualter, with the full Board assuming Audit and Risk Committee functions until further notice. The company’s earlier strategic review process explored partnerships, licensing, mergers, asset sales and alternative capital structures, but no transaction had emerged by the end of the quarter. The immediate sequence is now tightly defined: settle creditors, lodge audited accounts, satisfy ASX reinstatement requirements and secure capital before the remaining CDH17 option can move beyond feasibility work.